expressed, PD-L1 was up-regulated in NSCLC compared with the adjacent tissues. CD8+ TILs could be seen in tumor stroma and nest. With univariate analysis, we found that the down-expression of MHC-I had an association with poor relapse-free survival (RFS) and overall survival (OS) in NSCLC patients (P ¼ 0.007 and P ¼ 0.001). RFS and OS in PD-L1À group tended to be longer than that of PD-L1+ group, but the difference was not significant (P > 0.05). Based on the distribution of CD8+ TILs, patients were divided into three groups: immune-inflamed group, immune-excluded group and immune-desert group. RFS and OS of patients with the immune-inflamed phenotype (CD8 inflamed ) were longer than patients with the immune-excluded and immune-desert phenotype (CD8 noninflamed ) (P ¼ 0.013 and P ¼ 0.015). Besides, patients were divided into four subgroups based on the PD-L1 and CD8+ Background: MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in pathogenesis of human cancers. Several miRNAs have been shown to involve in regulation of tumor development and metastasis of lung cancer through alteration of gene networks. The aim of this study was to identify a panel of miRNAs as potential diagnostic and therapeutic target in lung cancer. Method: Quantitative reversetranscriptase PCR was applied to evaluate the expression of selected 12 cancer-associated microRNAs in 79 patients' samples with primary lung cancer and matched metastatic lymph node tissues. Protein expression were detected by immunoblotting. Cell migration, invasion and invadopodia formation were assessed in vitro by wound-healing, transwell assay and immunofluorescence, respectively. The dual-luciferase reporter assay was used to identify the direct target of miRNA. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results: miR-145 was significantly lower in LN-positive NSCLC (P < 0.05), while expression of miR-10b was significantly higher (P < 0.05). Expression of both miR-145 and miR-10b was correlated with lymph node metastasis in NSCLC (both Ps < 0.001). Functional experiments reveal that miR-10b facilitated the migration and invasion of lung cancer cell line A549, while miR-145 suppressed the migration and invasion capacity of A549 in vitro. Additionally, low miR-146b-5p expression level was associated with poor prognosis in NSCLC patients, and miR-146b was an independent prognostic factor for NSCLC patients. In vitro gain-of-function and lossof-function assays revealed that miR-146b-5p suppressed cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest in NSCLC. Background: To assess the baseline neurocognitive functions in patients with brain metastasis from lung cancer before receiving radiotherapy, and determine the risk factors for neurocognitive function impairment. Method: The clinical data of patients suffering from brain metastasis from lung cancer who were admitted to Guangdong Sanjiu Brain Hospital from January 2017 to December 2017 were retrospectively analyzed. At 1-2 weeks before radiotherapy for brain metastasis, several scales were used to assess the neurocognitive functions in the 74 patients. Psychometricians assessed and divided the neurocognitive functions into 4 levels, namely normal, mild impairment, moderate impairment and severe impairment. All analyses were performed using the statistical
were longer than patients with PD-L1+/CD8
non-inflamed andPD-L1À/ CD8 non-inflamed . Patients with PD-L1+/CD8 non-inflamed experienced the worst RFS and OS. With multivariate analysis, we found that MHC-I and CD8+ TILs might be independent prognostic factors in surgically resected NSCLC. Conclusion: MHC-I and CD8+ TILs expression had a close association with patients prognosis in this study. The combination of PD-L1 and CD8+ TILs, instead of PD-L1 alone, suggested impressive prognostic values in NSCLC patients. It worth further study to confirm the clinical value of MHC-I, PD-L1 and CD8 TILs expressions in the patients with surgically resected NSCLC. Keywords: Non-Small Cell Lung Cancer, major histocompatibility complex class I, programmed cell death ligand-1, tumor infiltrating lymphocyte Background: MicroRNAs (miRNAs) are small non-coding RNAs that play a crucial role in pathogenesis of human cancers. Several miRNAs have been shown to involve in regulation of tumor development and metastasis of lung cancer through alteration of gene networks. The aim of this study was to identify a panel of miRNAs as potential diagnostic and therapeutic target in lung cancer. Method: Quantitative reversetranscriptase PCR was applied to evaluate the expression of selected 12 cancer-associated microRNAs in 79 patients' samples with primary lung cancer and matched metastatic lymph node tissues. Protein expression were detected by immunoblotting. Cell migration, invasion and invadopodia formation were assessed in vitro by wound-healing, transwell assay and immunofluorescence, respectively. The dual-luciferase reporter assay was used to identify the direct target of miRNA. The Kaplan-Meier and log-rank test were performed to quantify the survival functions in two groups. Results: miR-145 was significantly lower in LN-positive NSCLC (P < 0.05), while expression of miR-10b was significantly higher (P < 0.05). Expression of both miR-145 and miR-10b was correlated with lymph node metastasis in NSCLC (both Ps < 0.001). Functional experiments reveal that miR-10b facilitated the migration and invasion of lung cancer cell line A549, while miR-145 suppressed the migration and invasion capacity of A549 in vitro. Additionally, low miR-146b-5p expression level was associated with poor prognosis in NSCLC patients, and miR-146b was an independent prognostic factor for NSCLC patients. In vitro gain-of-function and lossof-function assays revealed that miR-146b-5p suppressed cell proliferation, clonogenicity, migration/ invasion and also induced G1 arrest in NSCLC. Background: To assess the baseline neurocognitive functions in patients with brain metastasis from lung cancer before receiving radiotherapy, and determine the risk factors for neurocognitive function impairment. Method: The clinical data of patients suffering from brain metastasis from lung cancer who were admitted to Guangdong Sanjiu Brain Hospital from January 2017 to December 2017 were retrospectively analyzed. At 1-2 weeks before radiotherapy for brain metastasis, several scales were used to assess the neurocognitive functions in the 74 patients. Psychometricians assessed and divided the neurocognitive functions into 4 levels, namely normal, mild impairment, moderate impairment and severe impairment. All analyses were performed using the statistical package R, to analyze the relationships between cognitive assessment results and clinical characteristics, and Kappa test was used to analyze the consistency of physical examination and cognitive scales for assessing the neurocognitive functions in patients. Finally, the related factors were analyzed with univariate and multivariate analysis. Results: Clinical physical examination showed that there were 21 cases of cognitive decline (28.4%) and 53 cases of normal cognition (71.6%), while the results of cognitive scales revealed that there were 6 cases of normal cognition (8.1%), 26 cases of mild impairment (35.1%), 2 cases of moderate impairment (2.7%) and 40 cases of severe impairment (54.1%). The result of Kappa test showed Kappa<0.4, indicating that the differences between cognitive scale results and physical examination were significant. The univariate analysis on the factors related to neurocognitive function impairment revealed that the risk factors that may affect the degree of neurocognitive function impairment included age, KPS score, GPA score, RPA class and the number of metastatic tumors; and the multivariate analysis showed that age and RPA class>2 were the independent risk factors for neurocognitive function impairment. Background: Interstitial lung diseases (ILD) frequently occur in patients with lung cancer. The optimal treatment strategy for non-smallcell lung cancer (NSCLC) patients with ILD remains unclear. We reviewed the efficacy and safety of surgery, chemotherapy, and radiotherapy. Method: We analyzed the medical records of patients with clinical stage IIIA-N2 NSCLC with ILD who were treated at our hospital between 2001 and 2016. Results: 505 patients with clinical stage IIIA-N2 NSCLC were included. Of these patients with ILD, treatments included surgical resection (S) in 14 patients, chemoradiotherapy (CRT) in 7 patients, palliative chemotherapy (C) in 7 patients and palliative radiotherapy in one patient. The median follow-up period was 38 months. The patients' characteristics were as follows S/CRT/C: male, 26/6/7 patients; median age (range), 69 (58-82)/69 (60-75)/69 (35-82) years. Of the S, pathological stage IA/IIA/IIB/IIIA/IIIB, 1/1/2/ 9/1 patients. The median progression-free survival times were 9.5 months (95% CI: 5.3-45.3 months) in S, 45.9 months (95% CI: 7.2 months-not reached [NR] ) in CRT, and 5.0 months (95% CI: 0.5-10.5 months) in C. The median overall survival time were 33.3 months (95% CI: 9.8 months-NR) in S, 45.9 months (95% CI: 8.3 months-NR) in CRT, and 9.9 months (95% CI: 1.6-42.4 months) in C. One patient died within 1 month of surgical resection. Acute exacerbations of ILD (AE-ILD) were noted in 14 % of the patients; 3 patients after surgery and 1 patient after chemoradiotherapy. Conclusion: The surgery and chemoradiotherapy can be considered as a treatment option for selected patients with IIIA-N2 NSCLC with ILD, with careful management after sufficient evaluation of the risks and the benefits. Keywords: interstitial lung diseases, stage IIIA, nsclc
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